The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

Provided herein are compositions, systems, and methods for delivering an effector protein into a cell. The present disclosure, in some aspects, provide novel proteins delivering an effector protein into a cell. The novel proteins are supernegatively charged proteins derived from highly anionic proteins identified from the proteome (e.g., human proteome). The novel protein tags can be associated (e.g., covalently or nocovalently) with the protein to be delivered to facilitate delivery of the effector protein into a cell.

A peptide for regulating fat metabolism is described. The peptide is selected from the group consisting of: YLGASVPSPDPLEP (SEQ ID NO: 1); YLNNGLGAPAPYPDPLEP (SEQ ID NO: 4); PDPLEP (SEQ ID NO: 14); and PSPDPLEP (SEQ ID NO: 16).

Provided herein are compositions and methods for altering sensitivity of target cells to killing by γδ T cells.

A reference standard set for BNP measurement, including a plurality of reference standards including BNP-32 and proBNP, wherein the ratio BNP-32/proBNP (mole ratio) differs between the reference standards, and when a reference standard having a high mole ratio and a reference standard having a low mole ratio are compared, the BNP concentration, which is the sum total of the BNP-32 concentration and the proBNP concentration, is lower in the reference standard having a high mole ratio than in the reference standard having a low mole ratio. The present invention makes it possible to provide: a reference standard set for BNP measurement, whereby, when the BNP concentration value of a specimen measured by a certain BNP measurement method and the BNP concentration value of the specimen measured by another BNP measurement method are corrected using the reference standard set for BNP measurement, the corrected measurement values can be made to more closely coincide in comparison with a case in which the measurement values are corrected using a conventional reference standard; and a method for correcting, using the reference standard set for BNP measurement, the measured BNP concentration value of a specimen.

A reference standard set for BNP measurement, including a plurality of reference standards including BNP-32 and proBNP, wherein the ratio BNP-32/proBNP (mole ratio) differs between the reference standards, and when a reference standard having a high mole ratio and a reference standard having a low mole ratio are compared, the BNP concentration, which is the sum total of the BNP-32 concentration and the proBNP concentration, is lower in the reference standard having a high mole ratio than in the reference standard having a low mole ratio. The present invention makes it possible to provide: a reference standard set for BNP measurement, whereby, when the BNP concentration value of a specimen measured by a certain BNP measurement method and the BNP concentration value of the specimen measured by another BNP measurement method are corrected using the reference standard set for BNP measurement, the corrected measurement values can be made to more closely coincide in comparison with a case in which the measurement values are corrected using a conventional reference standard; and a method for correcting, using the reference standard set for BNP measurement, the measured BNP concentration value of a specimen.

Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo. The agonists are delivered to an individual at a dose sufficient to reduce hypertension and ischemic injury, and to reduce cardiotoxicity associated with chemotherapeutic agents.

A novel long-acting acylated oxyntomodulin peptide analogue having dual agonism on GLP-1 and glucagon receptors (dual GLP-1R/GlucagonR agonism) and a pharmaceutical composition including the same are disclosed. The novel long-acting acylated oxyntomodulin peptide analogue and the composition are useful for the prevention and treatment of obesity and overweight, or non-insulin-dependent diabetes accompanied by obesity and overweight. The acylated oxyntomodulin peptide analog has dual agonism for GLP-1/glucagon receptors and has an excellent increased in vivo half-life, and the pharmaceutical composition containing the same is useful for the treatment of metabolic diseases such as obesity and diabetes.

Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.

The present disclosure relates to anti-mullerian hormone (AMH) analogues, more particularly AMH analogues which are agonists of the AMH type II receptor (AMHR2). More particularly, the present disclosure relates to AMH analogues having a modification present within one or more of amino acid residues 533 to 548 of SEQ ID NO:1.